Data from the GRACE study will be published in the September 21st issue of the Annals of Internal Medicine. GRACE is the largest-ever study of treatment-experienced adult women with HIV-1 to examine gender differences in response to HIV therapy. Sponsored by Tibotec Therapeutics Clinical Affairs, a division of Centocor Ortho Biotech Services, LLC, the GRACE study enrolled 67 percent women, demonstrating that it is possible to recruit large numbers of women into U.S.-based HIV treatment studies. The company has launched to share learnings from the GRACE study and other information for women living with HIV.

Merck introduced GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], the world's first cervical cancer vaccine, a vaccine that can also help to prevent vulvar and vaginal cancers and genital warts caused by HPV types 6, 11, 16 and 18.  The paper being published in JAMA on Aug. 19 by the Centers for Disease Control and Prevention (CDC) is another important milestone in the medical community's ongoing effort to monitor the safety of vaccines, including GARDASIL.

When you Archive an Article, the content is put into a state which removes it from your site as published content. The Article is still available from within the Control Panel and can be retrieved for editing or republishing purposes. Trashed Articles are just one step from being permanently deleted but are still available until you Remove them from the Trash Manager. You should use Archive if you consider an Article important, but not current. Trash should be used when you want to delete the content entirely from your site and from future search results.

A new genetic substudy of PLATO showed that the effects on a combined primary endpoint of cardiovascular death, myocardial infarction, or stroke seen in Acute Coronary Syndromes (ACS) patients who received the investigational oral antiplatelet treatment, ticagrelor (BRILINTA™), were maintained, whether or not they had the genetic variability that has been previously shown to affect a patient’s response to clopidogrel. The substudy is the first to look at both efficacy and bleeding endpoints of ACS patients treated with ticagrelor who carry variations in the CYP2C19 and ABCB1 genes. The data were presented today at the European Society of Cardiology (ESC) congress in Stockholm, Sweden and simultaneously published in The Lancet.

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced final results from a retrospective study including more than 260,000 patients that showed the risk of acute pancreatitis among initiators of BYETTA(R) (exenatide) injection was not increased compared to initiators of other antidiabetic therapies. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.

Sign up via our free email subscription service to receive notifications when new information is available.